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Summary. Background: Rhodocytin, a disulfide-linked heterodimeric C-type lectin from Calloselasma rhodostoma consisting of a-subunits and b-subunits, induces platelet aggregation through C-type lectin-like receptor 2 (CLEC-2). CLEC-2 is a physiological binding partner of podoplanin (PDPN), which is expressed on some tumor cell types, and is involved in tumor cell-induced platelet aggregation and tumor metastasis. Thus, modified rhodocytin may be a possible source of anti-CLEC-2 drugs for both antiplatelet and antimetastasis therapy. However, its molecular function has not been well characterized, because of the lack of recombinant rhodocytin that induces platelet aggregation. Objective: To produce recombinant rhodocytin, in order to verify its function with mutagenesis, and to develop an anti-CLEC-2 drug based on the findings. Methods: We used Chinese hamster ovary cells to express recombinant rhodocytin (wildtype [WT] and mutant), which was analyzed for induction/inhibition of platelet aggregation with light transmission aggregometry, the formation of multimers with blue native PAGE, and binding to CLEC-2 with flow cytometry. Finally, we investigated whether mutant rhodocytin could suppress PDPN-induced metastasis in an experimental lung metastasis mouse model. Results: Functional WT] rhodocytin (aWTbWT) was obtained by coexpression of both subunits. Asp4 in a-subunits of rhodocytin was required for CLEC-2 binding. aWTbWT formed a heterooctamer similarly to native rhodocytin. Moreover, an inhibitory mutant of rhodocytin (aWTbK53A/R56A), forming a heterotetramer, bound to CLEC-2 without inducing platelet aggregation, and blocked CLEC-2
Introduction
Platelets play a central role in thrombosis and hemostasis, and are closely involved in tumor progression, particularly in tumor metastasis [1] [2] [3] . The interaction between platelets and circulating tumor cells often results in tumor cell-induced platelet aggregation, facilitating hematogenous tumor metastasis, as deduced from studies using mouse models of experimental metastasis [4, 5] .
C-type lectin-like receptor 2 (CLEC-2) is a receptor for the platelet-activating snake venom rhodocytin [6] . CLEC-2 is a physiological binding partner of podoplanin (PDPN), which is expressed on some tumor cell types, and is involved in tumor cell-induced platelet aggregation and tumor metastasis [4, 7] . CLEC-2 depletion with a specific antibody suppresses PDPN-expressing tumor metastasis and thrombus formation in the lungs, and subsequently improves the prognosis of tumor-bearing mice [8] . In an experimental lung metastasis model in mice, an anti-PDPN blocking antibody significantly inhibits the number of metastatic lung nodules consisting of PDPN-expressing tumor cells [9] . Platelet/ megakaryocyte-specific CLEC-2-deficient mice have no bleeding tendency to a minimal bleeding tendency [10] . These reports suggest that the CLEC-2-PDPN interaction could be a promising target for antiplatelet and antitumor metastatic drugs.
Rhodocytin (also called aggretin), a snake venom protein obtained from the Malayan pit viper Calloselasma rhodostoma, induces platelet aggregation through CLEC-2 clustering with multiple binding sites [11, 12] . It is classified as a snake venom C-type lectin (snacle), having a basic heterodimeric structure with two subunits, a (136 amino acids) and b (123 amino acids), that are nearly always linked covalently via a disulfide bond [13] . Multimer formation by a-subunits and b-subunits of rhodocytin contributes to clustering of CLEC-2 by providing plural binding sites with rhodocytin, leading to platelet activation. However, further investigations are required to obtain more details. We hypothesized that mutant rhodocytin binding to CLEC-2 without causing CLEC-2 clustering could act as a CLEC-2 blocker. Although native rhodocytin has been structurally analyzed [12, 14, 15] , its molecular function is not well characterized, as constructing recombinant rhodocytin that induces platelet aggregation is difficult, possibly because it is hard to generate a covalent association between the a-subunit and the b-subunit. Recombinant expression will help in interpreting the function of rhodocytin subunits, and will be useful for innovative medicine development.
Here, we successfully generated functional wild-type (WT) rhodocytin for the first time. By using site-directed mutagenesis and deletion mutant approaches, we determined that Asp4 in the a-subunits is one of the critical sites for induction of platelet aggregation, and that WT recombinant rhodocytin assumes a heterooctameric form. We found that mutant rhodocytin inhibits CLEC-2-PDPN interaction-dependent platelet aggregation and experimental lung metastasis. These findings provide information on the molecular characterization of rhodocytin, and suggest that functionally modified rhodocytin mutants could contitute a potential source of CLEC-2-targeting therapeutic agents.
Materials and methods

Reagents and antibodies
Purified native rhodocytin and rabbit polyclonal antibody against habu factor IX/X-binding protein (habu IX/X-bp) were kindly provided by Y. Shin (Kogakuin University, Tokyo, Japan). We used this antibody as an anti-rhodocytin antibody because rhodocytin cross-reacted with the antibody against habu IX/X-bp [11] . Mouse monoclonal anti-b-actin (#926-42212) was from LI-COR Bioscience (Lincoln, NE, USA). Rabbit IgG isotype control (sc-2027) was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Alexa 488-conjugated goat anti-rabbit IgG (Alexa 488-rIgG) and Alexa 488-conjugated human IgG (Alexa 488-hIgG) were from Thermo Fisher Scientific (San Jose, CA, USA). Collagen (Collagen Reagent Horm) was from Takeda Austria (Linz, Austria). Doxycycline hyclate was from Sigma-Aldrich Chemical (St Louis, MO, USA).
Construction of expression vectors for rhodocytin
The cDNA sequences of a-subunits and b-subunits of rhodocytin were obtained from a previous study [16] . The signal sequence of the b-subunit for secretion into the extracellular space is commonly used for expression of a-subunits and b-subunits of rhodocytin. These sequences were codon-optimized for mammalian expression, artificially synthesized, and cloned into the pUC57-Amp vector by GENEWIZ (South Plainfield, NJ, USA). The insert was ligated into a pCMV expression vector with the 'simple cloning' method without restriction and ligation enzymes [17] . Each PCR amplicon for the insert and the vector was prepared with Q5 DNA polymerase (NEB, Ipswich, MA, USA). Site-directed mutagenesis was performed by PCR with a pair of oligonucleotide primers designed with mismatching nucleotides at the centers of the primers. Primer pairs were from Life Technologies (Gaithersburg, MD, USA). DNA sequencing was performed by Macrogen Japan (Tokyo, Japan). The expression constructs for a-subunits and b-subunits in rhodocytin are shown in Fig. S1 .
Transient transfection of Chinese hamster ovary (CHO) cells by electroporation
CHO cells were obtained from The Health Science Research Resources Bank (Osaka, Japan) and maintained in Isocove's modified Dulbecco's medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin (Thermo Fisher Scientific). Transient transfection was performed as previously described [7] . In brief, 400 lL of CHO cells at 2.5 9 10 7 cells/mL was placed into a 4-mm electroporation cuvette with 40 lg of total expression vector. Cotransfection of two vectors was performed by mixing equal amounts of both vectors. CHO cells were electroporated with Gene Pulser (Bio-Rad, Hercules, CA, USA) in Cytomix buffer containing 240 mM KCl, 0.3 mM CaCl 2 , 20 mM K 2 HPO 4 .3H 2 O and KH 2 PO 4 , 50 mM HEPES, 4 mM EGTA, and 10 mM MgCl 2 , supplemented with 50 mM ATP and fresh reduced glutathione (3.08 mg mL À1 ). Electroporation was performed at 950 lF and 250 V. At 12 h post-transfection, the growth medium was replaced with Opti-MEM medium (Life Technologies). At 3-5 days post-transfection, the conditioned media and whole cell lysate with phosphate-buffered saline (PBS) and 1% Triton X-100 were collected and analyzed for expression and platelet aggregation.
Western blotting
Western blotting was performed as described previously [18] . In brief, the conditioned media and whole cell lysate expressing recombinant rhodocytin were dissolved in SDS sample buffer, separated by 4-12% SDS-PAGE, electrotransferred, and western-blotted with anti-rhodocytin antibody or anti-b-actin antibody.
Platelet preparation
To obtain human platelets, venous blood from healthy drug-free volunteers was collected into 10% sodium citrate. This study was approved by the Ethical Committee at the University of Yamanashi, and written informed consent was provided according to the Declaration of Helsinki. To obtain murine platelets, WT C57BL/6 and platelet/megakaryocyte-specific CLEC-2 conditional knock-out (KO) mice (Clec1b flox/flox ;PF4-Cre) [18] were killed with diethyl ether, and blood collected by postcaval puncture was added to 100 lL of acid-citrate-dextrose. This study was approved by the Animal Care and Use Committee of the University of Yamanashi. Washed human and murine platelets were obtained by centrifugation (220 9 g for 10 min) as described previously, with prostacyclin to prevent activation during the isolation procedure [19] . Both platelets were resuspended in calcium-free modified Tyrode (CFT) buffer [19] .
Platelet aggregation assay
Washed platelets (100 lL, 2 9 10 8 mL À1 ) obtained from humans or mice (WT or CLEC-2 KO) were stirred at 1400 r.p.m. in small cuvettes at 37°C for 1 min on a platelet aggregometer (MCM Hema Tracer 712; MC Medical, Tokyo, Japan). Light transmission of washed platelets after addition of 10 lL of test solution (conditioned medium, rhodocytin, or collagen) was monitored for 10 min with CFT buffer as a reference.
To observe platelet aggregation induced by human PDPN (hPDPN)-expressing CHO (CHO/hPDPN) cells, human or murine washed platelets (1 9 10 9 mL À1 ) were incubated with mutant rhodocytin at 37°C for 5 min, and stimulated with 5 9 10 6 mL À1 or 1 9 10 6 mL À1 CHO/hPDPN cells; platelet aggregation was monitored for 15 min with an aggregometer.
Recombinant rhodocytin purification
Each recombinant protein was expressed in CHO cells. The media containing recombinant rhodocytin were collected at 3-5 days post-transfection and pooled. Cell debris was collected by centrifugation (9000 9 g, 4°C, 30 min), and the resulting supernatant was filtered through a 0.45-lm filter (Millipore, Bedford, MA, USA) and subjected to gel filtration and anion exchange column chromatography with the AKTA prime plus protein purification system (GE Healthcare Life Sciences, Piscataway, NJ, USA). In brief, after adjustment of the pH to 8.0 with 1 M NaOH, the supernatant was loaded onto three-connected 5-mL HiTrap Q HP column (GE Healthcare Life Sciences) previously equilibrated with 50 mM Tris-HCl (pH 8.0), and eluted in a 0-1 M NaCl gradient. Also, the purified protein was loaded onto a HiPrep 26/ 60 Sephacryl S-200 HR (GE Healthcare Life Sciences) previously equilibrated with PBS. All chromatography processes were performed at room temperature. The protein purity was checked with SDS-PAGE and blue native PAGE. The proteins obtained were stored at either 4°C or À 80°C.
Flow cytometry
To detect direct binding of human CLEC-2 (hCLEC-2), 293T-REx cells expressing hCLEC-2 (5 9 10 6 cells mL À1 ) pretreated with doxycycline were preincubated with 6 lg mL À1 rhodocytin or conditioned media for 15 min at room temperature. After excess rhodocytin had been eluted by centrifugation (500 9 g for 5 min), cells were incubated with 10 lg mL À1 rabbit IgG isotype control or anti-rhodocytin antibody for 20 min at room temperature, and unbound antibodies were then removed. The samples were then stained with Alexa 488-rIgG, and analyzed with an Accuri C6 flow cytometer (BD Biosciences, San Jose, CA, USA), as previously described [6] .
To confirm inhibition of the association between CLEC-2 and PDPN, 293T-REx cells expressing hCLEC-2 (5 9 10 6 cells mL À1 ) were treated with recombinant rhodocytin (0.6, 6 or 60 lg mL
À1
) and hPDPN-human Fc (hPDPN-hFC) or human Fc chimeras (hFCs) (10 lg mL À1 ) for 20 min at room temperature; this was followed by removal of unbound proteins. The samples were then stained with Alexa 488-hIgG, and analyzed with an Accuri C6 flow cytometer.
Blue native PAGE
Blue native PAGE was performed with the Bis-Tris Native PAGE system (Thermo Fisher Scientific), according to the manufacturer's instructions. In brief, various recombinant rhodocytin samples (5 lg each) were separated by 5-16% blue native gel electrophoresis. Gels were stained with Coomassie brilliant blue.
Experimental lung metastasis assay
The experimental lung metastasis assay was performed as described previously [9] . In brief, CHO/hPDPN cells were harvested, washed, and resuspended in PBS (2.5 9 10 6 cells mL À1 ). The cells were then inoculated via intravenous injection (2.5 9 10 5 cells per mouse) into female BALB/c-nu/nu mice. Mutant rhodocytin (24 lg per mouse) or PBS was then administered by retro-orbital injection 30 min prior to CHO/hPDPN cell transplantation. The mice were killed 14 days after injection of CHO/hPDPN cells, and their lungs were collected. The surface lung metastatic foci were counted, and lung weight was measured. The platelet counts were quantified with a Sysmex XE-2100 (Sysmex, Kobe, Japan). Paraformaldehyde-fixed sections of the lung tissue were stained with hematoxylin and eosin (H&E), observed under a light microscope, and photographed.
Statistical analysis
Statistical analyses were performed with GRAPHPAD PRISM 6 software. Student's t-test and one-way ANOVA were used to determine the statistical significance of the data. Data are presented as mean AE standard error of the mean.
Results
Recombinant rhodocytin expression
To generate functional recombinant rhodocytin, we separately constructed expression vectors of a-subunits and b-subunits of rhodocytin (Fig. S1 ). After transient transfection with electroporation in combination with the WT a-subunit (aWT) and the WT b-subunit (bWT) into CHO cells, the expressed proteins in the conditioned media and whole cell lysate were analyzed by western blotting (Fig. 1A) . When aWT and bWT were cotransfected into the cells at the same time, both subunits were secreted into the medium ( Fig. 1A ; lane 4). Rhodocytin subunits were not secreted into the medium when the C83A mutation in the a-subunit (aC83A) was used to disrupt the covalent association between the a-subunit and the b-subunit ( Fig. 1A ; lane 5). The a-subunit or bsubunit was also not secreted into the medium in a single transfection process ( Fig. 1A ; lanes 2 and 3). These findings suggest that covalent association between a-subunits and b-subunits in the cells is necessary for rhodocytin secretion.
To elucidate rhodocytin function in the conditioned medium, we used washed platelets from WT and megakaryocyte/platelet-specific conditional CLEC-2 KO mice and performed platelet aggregation assays. The conditioned medium (aWTbWT) permitted cotransfection with both aWT and bWT, and induced platelet aggregation in WT but not in CLEC-2 KO mice (Fig. 1B) . The conditioned medium contained approximately 5-10 lg mL À1 functional rhodocytin (Fig. S2A) .
We confirmed that the purified recombinant rhodocytin aWTbWT showed platelet aggregation ability equivalent to that of the native counterpart (Fig. S2B) . The platelet aggregation ability of rhodocytin was attenuated by adding N-terminal or C-terminal His tags, which are commonly used to facilitate protein purification (Fig. S3 ).
In addition, we examined the critical regions for secretion of the recombinant protein. a-Subunits with several N-terminal amino acids deleted (aDN1, aDN2, aDN3, and aDN4) cotransfected with bWT were secreted into the medium (Fig. S4A,C) . When aDN5 and aDN6 were cotransfected with bWT, these encoded proteins were not secreted in the medium ( Fig. S4C; lanes 9 and 10) . Single transfections of aWT, aDN4, aDN5, aDN6 or bWT resulted in no bands in the medium ( Fig. S4C; lanes 2-6) . The conditioned medium consisting of cells cotransfected with aDN3 + bWT or aDN4 + bWT did not induce aggregation of washed human platelets (Fig. S4B,D) . These results indicated that the N-terminal region in the a-subunit was critical for both secretion and induction of platelet aggregation.
Asp4 in the a-subunit is required for induction of platelet aggregation
To identify specific residue(s) in rhodocytin that are necessary for secretion and induction of platelet aggregation, we performed alanine substitution mutagenesis within the N-terminus of the a-subunit (aG1A, aL2A, aE3A, aD4A, aC5A, aD6A, and aC16A), and analyzed expression during cotransfection with bWT ( Fig. 2A) . aC16 forms intramolecular disulfide bonds with aC5 [14, 15] . aG1AbWT, aL2AbWT, aE3AbWT, aD4AbWT and aD6AbWT were detected in the medium ( Fig. 2A ; lanes 3-6 and 8), with the levels being almost similar. In contrast, aC5A and aC16A were not secreted into the medium ( Fig. 2A; lanes 7 and 9) , suggesting that the intramolecular disulfide bond between Cys5 and Cys16 in the a-subunit may be essential for rhodocytin secretion. Mutant rhodocytin aD4AbWT did not induce platelet aggregation (Fig. 2B) . Flow cytometric analysis with 293T-REx cells expressing hCLEC-2 showed that aWTbWT, but not aD4AbWT, bound to CLEC-2 (Fig. 2C) . These results indicate that Asp4 in the a-subunit is one of the critical sites for the induction of platelet aggregation.
Multimer formation with a-subunits and b-subunits in rhodocytin
Rhodocytin multimer clusters CLEC-2 to induce platelet aggregation [12] . The mechanisms for multimer formation from heterodimers in rhodocytin are still controversial. Although hydrogen bonds between two a-subunits are involved in multimer formation [12] , we could not obtain the supporting data (Fig. S5) . However, these data suggested that the homologous residues located at Arg28 and Lys31 in the b-subunit contributed to the ability to induce platelet aggregation and bind to CLEC-2 (Fig. S5) . We hypothesized that hydrogen bonds exist between acidic amino acids in the a-subunit and basic amino acids in the b-subunit with a disulfide bond. To investigate rhodocytin multimerization, we generated several mutants of the b-subunit to rupture the multimer. Mutation sites and the schematic model of the rhodocytin multimer were obtained from the Protein Data Bank (ID code 3WWK; Fig. S6 ). These mutant rhodocytins coexpressing the mutant b-subunit with aWT were secreted into the medium (Fig. 3A) . The medium including WT rhodocytin aWTbWT or mutant rhodocytin aWTbR56A induced platelet aggregation (Fig. 3B) . However, mutant rhodocytins aWTbK53A/R56A, aWTbR58A/K60A, aWTbR28A/ K31A, aWTbR28A/K31A/K53A/R56A and aWTbR28A/ K31A/R58A/K60A failed to induce platelet aggregation (Fig. 3B) . Flow cytometry analysis confirmed binding of aWTbWT, aWTbK53A/R56A, aWTbK28A/R31A and aWTbK28A/R31A/K53A/R56A to 293T-REx cells expressing hCLEC-2 (Fig. 3C) . To directly assess rhodocytin assembly, we performed blue native PAGE with purified recombinant rhodocytin. Native rhodocytin, WT rhodocytin aWTbWT and mutant rhodocytin aD4AbWT were found to measure~120 kDa, indicating heterooctamer formation ( Fig. 3D; lanes 1, 2, and 6 ). aWTbK53A/R56A, aWTbK28A/R31A and aWTbK28A/ R31A/K53A/R56A were probably formed as heterotetramer, heterotrimer, and heterodimer, respectively ( Fig. 3D; lanes 3-5) . SDS-PAGE results for aWTbWT and aWTbK53A/R56A under reducing and non-reducing conditions showed that the band patterns of both recombinant proteins were the same in both conditions (Fig. S7) , suggesting that aWTbK53A/R56A forms an ab heterodimer with a disulfide bond and aWTbWT, but that aWTbK53A/R56A is a heterotetramer distinct from a heterooctamer, aWTbWT, through several ionic interactions. It has also been suggested that aWTbK53A/R56A binds to CLEC-2 but cannot induce platelet aggregation because of insufficient CLEC-2 clustering by heterotetramer (Fig. 3) .
Inhibition of the interaction between CLEC-2 and rhodocytin or PDPN by mutant rhodocytin
Because aWTbK53A/R56A binds to CLEC-2 but cannot activate platelets, this mutant may be used as a CLEC-2 blocker. We checked whether aWTbK53A/R56A, aWTbR58A/K56A, aWTbK28A/R31A, aWTbK28A/R31A/ K53A/R56A and aWTbK28A/R31A/R58A/K60A lacking the ability to induce platelet aggregation inhibited CLEC-2-mediated rhodocytin-induced platelet aggregation. Addition of conditioned medium including aWTbK53A/ R56A or aWTbR58A/K60A completely inhibited CLEC-2-dependent platelet aggregation, whereas medium including aWTbK28A/R31A/K53A/R56A, aWTbK28A/R31A/ R58A/K60A or aWTbK28A/R31A caused minimal to no inhibition (Fig. S8A) . To confirm that mutant rhodocytin inhibited CLEC-2-dependent platelet aggregation, we monitored platelet aggregation with a final concentration of 0.6 lg mL À1 rhodocytin after incubation with mutant rhodocytin and washed human platelets. aWTbK53A/ R56A and aWTbK28A/R31A/K53A/R56A dose-dependently inhibited platelet aggregation by rhodocytin. The final concentrations giving complete inhibition were 192 ng mL À1 for aWTbK53A/R56A and 48 lg mL À1 for aWTbK28A/R31A/K53A/R56A (Fig. 4A) . The inhibitory effects were CLEC-2-specific, and aWTbK53A/R56A inhibited CLEC-2-mediated platelet aggregation but not glycoprotein VI-mediated platelet aggregation by collagen (Fig. S8B) .
Next, to assess the inhibitory ability against interaction between CLEC-2 and PDPN, flow cytometry analysis was performed for CLEC-2 detection with hPDPN-hFC after incubation with 293T-REx cells expressing CLEC-2 and recombinant mutant rhodocytin. We found that the interaction between CLEC-2 and PDPN was dose-dependently blocked by native rhodocytin, aWTbWT, and aWTbK53A/R56A (Fig. 4B) . However, aWTbK28A/ R31A and aWTbK28A/R31A/K53A/R56A had weak inhibitory effects on the interaction, which is consistent with the weak inhibitory effect on platelet aggregation.
Inhibition of PDPN-induced hematogenous metastasis by mutant rhodocytin
We investigated whether mutant rhodocytin inhibits CLEC-2-dependent platelet aggregation induced by CHO/ hPDPN cells. Mutant rhodocytin aWTbK53A/R56A completely inhibited PDPN-induced platelet aggregation in humans (final concentration of 6 lg mL À1 ) and mice (final concentration of 60 lg mL
À1
; Fig. 5A,B; Fig. S9 ). We then examined whether mutant rhodocytin could suppress PDPN-induced pulmonary metastasis in an experimental lung metastasis model in mice. Injection of CHO/hPDPN cells into nude mice with PBS or aD4AbWT (24 lg per mouse), which could not bind to CLEC-2, led to the development of multiple lung ). After excess PDPN had been eluted by centrifugation, cells were incubated with Alexa 488-conjugated antihuman IgG and analyzed by flow cytometry. Red line: hPDPN-hFC. Green fill: hPDPN-hFC + rhodocytin. Gray fill: hFC. aWT, wild-type asubunit; bWT, wild-type b-subunit; PBS, phosphate-buffered saline. metastatic foci (Fig. 5C) . Injection of CHO/hPDPN with aWTbK53A/R56A (24 lg per mouse) significantly reduced the number of metastatic lung nodules (P < 0.01; Fig. 5D ). Lung weight was also reduced significantly in mice injected with CHO/hPDPN and aWTbK53A/R56A as compared with those injected with washed, and resuspended in phosphate-buffered saline (PBS) (2.5 9 10 6 cells mL À1 ). Then, the cells were inoculated intravenously (2.5 9 10 5 cells per mouse) into the lateral tail vein of female BALB/c-nu/nu mice (five mice in each group). Mutant rhodocytin aWTbK53A/ R56A, aD4AbWT (24 lg per mouse) or PBS (100 lL per mouse) was inoculated by retro-orbital injection 30 min prior to CHO/hPDPN cell transplantation. aD4AbWT that could not bind to CLEC-2 was used as a control. After 14 days, the mice were killed, and surface lung metastatic foci were counted and measured. Representative pictures of the lungs (C), detailed numbers of the lung metastasis nodules (D), the weight of the lung (E) and the platelet count (F) in each mouse are shown. Data are represented as mean AE standard deviation. *P < 0.01 by t-test. (G) Representative haematoxylin and eosin-stained lung sections are shown. Scale bar: 50 lm. (H) The ratio of the tumor area to the total tumor and lung area was analyzed between mutant rhodocytin and the control group. *P < 0.01 by t-test. aWT, wild-type a-subunit; bWT, wild-type b-subunit; NS, not significant. PBS and aD4AbWT (Fig. 5E) . Platelet counts in both mice were similar to those in normal mice without CHO/ hPDPN cells injection at several time points ( Fig. 5F;  Fig. S10 ). H&E staining confirmed that mice injected with CHO/hPDPN cells and aWTbK53A/R56A showed significantly less metastasis to the lung (Fig. 5G,H) , indicating that aWTbK53A/R56A significantly inhibited pulmonary metastasis without platelet activation and resultant thrombocytopenia.
Discussion
Here, we report successful recombinant expression of rhodocytin that retained platelet aggregation activity. Using site-directed mutagenesis and a deletion mutant approach, we determined that Asp4 in the a-subunit is one of the critical sites for binding to CLEC-2 and induction of platelet aggregation, and that recombinant WT rhodocytin formed a heterooctamer similarly to the native counterpart. Moreover, we successfully developed a mutant rhodocytin that inhibited platelet aggregation and experimental lung metastasis in a CLEC-2-PDPN interaction-dependent manner.
Snacles, including rhodocytin, have a well-conserved heterodimeric structure formed by a disulfide bond between the a-subunit and b-subunit with three intramolecular disulfide bonds (six cysteine residues) in each subunit [13] . Developing recombinant snacles has been difficult because of the native structure, which is stabilized by numerous disulfide bonds. Here, we proved that cotransfection of plasmids encoding a-subunits and b-subunits cause the formation of disulfide bonds, presumably between Cys83 in the a-subunit and Cys75 in the b-subunit, leading to rhodocytin secretion outside the cells and platelet aggregation (Fig. 1A) . In addition, when the disulfide bond between Cys5 and Cys16 of the a-subunit was absent, rhodocytin could not be secreted into the culture medium ( Fig. 2A) . Our results suggest that both intermolecular and intramolecular disulfide bonds are important for rhodocytin structural stability and function.
Structural analysis has suggested that the N-terminal and C-terminal sequences of the a-subunit of rhodocytin are crucial for CLEC-2 binding [15] . Contiguous acidic amino acids (Glu3, Asp4, and Asp6) at the N-terminus of the a-subunit contribute to the binding between rhodocytin and CLEC-2 [15] . We found that only D4A mutation in the a-subunit led to an impairment in the ability to bind to CLEC-2 and induce platelet aggregation (Fig. 2) . Alanine substitutions at Tyr136, Pro135 or Leu134 of the C-terminus in the a-subunit did not affect the expression, secretion and platelet aggregation ability of rhodocytin (Fig. S11A,  B) . These substitutions, combined with the L2A mutation, partially attenuated the aggregation ability (Fig. S11C,D) . Furthermore, we found that N-terminal (DN1) or C-terminal (DC3) deletions in the a-subunit did not affect the ability of rhodocytin to induce platelet aggregation, whereas simultaneous deletion (DN1-DC3) resulted in complete loss of platelet aggregation ability (Fig. S12) , suggesting that the C-terminus of the a-subunit partially contributes to platelet aggregation through CLEC-2. The common ligand-binding site of snacles assumes a concave shape formed by the a-subunit and the b-subunit [13] . However, although this model has also been proposed for rhodocytin [14] , we could not prove that the binding site for CLEC-2 also assumes a concave shape.
Functional analysis of recombinant rhodocytin revealed that the mutant rhodocytin aWTbK53A/R56A binds to CLEC-2 but does not induce platelet aggregation. This mutant is a heterotetramer, probably because of the absence of hydrogen bonds between a-subunits and bsubunits, which are important for multimer formation. We suggest that WT heterooctameric rhodocytin clusters at least four CLEC-2 molecules, causing platelet aggregation, indicating that bimolecular CLEC-2 binding by heterotetrameric mutant rhodocytin aWTbK53A/R56A may be insufficient to trigger platelet aggregation. Importantly, this mutant almost completely inhibited CLEC-2 binding to rhodocytin or PDPN at low concentrations. However, heterodimeric mutant rhodocytin aWTbK28A/ R31A/K53A/R56A showed weaker inhibition of rhodocytin-induced platelet aggregation than heterotetrameric rhodocytin. The multimer formation may have an influence on the affinity for CLEC-2. We have summarized the results obtained with several rhodocytin mutants (Table S1 ). The model proposed in this study is shown in Fig. S13 .
A synthesized aggretin a-chain C-terminus (AACT, residues 106-136) and a non-cytotoxic 5-nitrobenzoate compound 2CP are CLEC-2 inhibitors that inhibit PDPNmediated platelet activation and tumor metastasis [5, 20] . Because integrin b 1 and CLEC-2 have been shown to be AACT binding targets, AACT affects rhodocytin-induced and collagen-induced platelet aggregation [20, 21] . 2CP selectively inhibits PDPN-induced but not rhodocytininduced platelet aggregation [5] . CLEC-2 binding affinities for rhodocytin and PDPN are equivalent to 1.01-3 lM and 24.5 lM, respectively [15, 22, 23] . As the CLEC-2 binding affinity for 2CP (33.2 AE 1.9 lM) is weaker than that for rhodocytin [5] , 2CP could not suppress the interaction between CLEC-2 and rhodocytin. We showed that rhodocytin blocked CLEC-2 and PDPN binding (Fig. 4) . The inhibitory mutant rhodocytin (aWTbK53A/R56A) specifically suppresses rhodocytin-induced or PDPN-induced platelet aggregation via CLEC-2, but does not inhibit collagen-induced platelet aggregation. The inhibitory mutant rhodocytin showed higher affinity and specificity than AACT and 2CP, probably because it has the same binding characteristics as WT rhodocytin.
The inhibitory rhodocytin mutant aWTbK53A/R56A significantly inhibited CLEC-2-PDPN interaction-dependent experimental lung metastasis in mice (Fig. 5C-H) .
The concentration of mutant rhodocytin required to suppress PDPN-dependent human platelet aggregation was approximately 1/10th of that required to suppress mouse platelet aggregation (Fig. 5A,B; Fig. S5 ). The CLEC-2 copy number per platelet is approximately 2000 in humans and 47 100 in mice [24, 25] . The difference in the inhibitory effect of mutant rhodocytin is attributable to the difference in CLEC-2 copy number on the platelet membrane between humans and mice. Therefore, in clinical use, drugs targeting CLEC-2 could be administered at lower concentrations than those indicated in animal experiment models.
In conclusion, our findings provide strong evidence that functionally modified recombinant rhodocytin is a potential source and a basis for the development of anti-CLEC-2 drugs for preventing and treating hematogenous metastasis of PDPN-positive tumors and PDPN-induced thrombosis.
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